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SCHIZOPHRENIA CARE AND ASSESSMENT
PROGRAM (SCAP): THE IMPACT OF CLINICAL
AND FUNCTIONAL CHARACTERISTICS AND
ANTIPSYCHOTIC MEDICATION TREATMENT
ON OUTPATIENT AND INPATIENT
PSYCHIATRIC UTILIZATION
Russo P1, Palmer LA1,Vasey J2
1The MEDSTAT Group, Inc, Washington, DC, USA; 2The
Pennsylvania State University, State College, PA, USA
OBJECTIVE: Examine the impact of clinical syndrome
and type of antipsychotic medication on outpatient and
inpatient utilization for participants in the U.S. SCAP.
METHODS: Baseline data used to predict 1-year outpa-
tient and inpatient utilization (n = 806). Psychotherapy,
clinic visits, rehabilitation treatment, day treatment and
hospitalizations examined. Presence of antipsychotics
coded for ﬁrst generation (reference group), second gen-
eration, both ﬁrst and second-generation, and no antipsy-
chotic use. Logistic and negative binomial regressions
using predicted values obtained through joint determina-
tion (SURE) of clinical/functional status conducted with
demographic variables as controls.
RESULTS: Persons with combination of ﬁrst and second-
generation antipsychotics exhibited higher likelihood 
(p < 0.001) and greater number of psychotherapy visits
(p < 0.001), higher likelihood of day treatment (p =
0.002) and shorter hospital length of stay (p = 0.03).
Persons prescribed only second-generation antipsychotics
had higher likelihood (p = 0.001) and greater number of
psychotherapy visits (p = 0.03), lower likelihood and
number of clinic visits lower (p = 0.05; p < 0.001) and
higher probability of rehabilitation (p = 0.04). Depression
(MADRS) and functionality (GAF) exhibited an inverse
relationship to number of clinic visits. Higher function-
ing led to lower probability (p = 0.001) of day treatment.
Higher QLS scores associated with higher likelihood of
day treatment (p < 0.001) and fewer inpatient days of care
(0.05).
CONCLUSION: This analysis indicates that antipsy-
chotic type impacts probability and number of outpatient
services and days of inpatient care; impact however is
mixed and warrants further investigation. Clinical and
functional status impact utilization; results suggest a
‘bimodal’ utilization effect. Individuals with higher 
functioning levels may require fewer services to maintain
community functioning; individuals with lower levels of
functioning may not be well enough to participate in 
outpatient services. Findings suggest medication and
functional status are signiﬁcant determinants of inpatient
and outpatient utilization; evaluation of these factors may
lead to better clinical management and policy decision-
making for persons with schizophrenia.
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IS DONEPEZIL COST-EFFECTIVE IN THE
TREATMENT OF ALZHEIMER’S DISEASE 
(AD)?
Sobolewski M1, Kuzniar J2, Splawinski J3, Marc M2
1University of Technology, Rzeszow, Poland; 2District Hospital
No2, Rzeszow, Poland; 3Independent Centre for Economic
and Pharmaceutical Research, Warsaw, Poland
OBJECTIVE: To estimate incremental cost-effectiveness
(ICE) of donepezil for mild or moderate AD as compared
with option of no treatment in Polish settings.
METHODS: We used Markov model developed by
Naumann et al. Model assumptions: treatment duration
and drug effect, 6 months; cohort of patients initially 
split by 50% into mild and moderate disease states; 50%
of patients on 5mg and 50% on 10mg daily dose of
donepezil. Data on costs by stage of disease including:
medications, medical equipment, home help and commu-
nity nurse, were taken from the Polish Alzheimer’s
Society. Study was conducted from a societal perspective.
Three types of outcome were estimated: expected costs,
years in state less than severe (SLS), and incremental 
costs per additional SLS per treated person over 5 years
projection.
RESULTS: The difference in expected costs per patient
over 12, 24, and 60 months of treatment was: US $634,
$520, and $408, respectively. Patients receiving donepezil
were predicted to spend additional 0.123 year in less than
severe AD compared with untreated patients. Incremen-
tal costs of SLS per treated person was $3,315/year. 
Sensitivity analysis revealed that ICE increased in paral-
lel with the percentage of patients being initially in the
mild AD. The difference in the total expected costs of
treatment was: $355 and $303 when cohort comprised
of 75% and 100% of patients with mild AD, respectively.
In these scenarios additional time spent in SLS AD was
0.151 and 0.179 year and incremental costs of SLS was
$2,364/year and $1,694/year, respectively. When the
duration of treatment and effects were projected for 1
year, incremental costs of SLS was $3,852/year.
CONCLUSION: Donepezil in the treatment of AD is
most cost-effective in mild stage of the disease and its
cost-effectiveness is reduced when treatment lasts >6
months.
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THE EFFECTS OF PANAX GINSENG ON
QUALITY OF LIFE:A PILOT STUDY
Reddy P, Ellis J
University of Connecticut, Storrs, CT, USA
OBJECTIVE: To assess the time-dependent effects of
Panax ginseng on health-related quality of life (HRQOL)
using a general health status questionnaire.
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METHODS: Subjects were randomized in a double-blind
manner to 200mg Panax ginseng (n = 15) or placebo (n
= 15) daily for 8 weeks. The Short Form-36 version 2 
(SF-36v2), a validated general health status questionnaire,
was used to assess HRQOL at baseline, 4 and 8 weeks.
HRQOL between the groups was compared using
repeated measures analysis of covariance. A p-value of
<0.05 was considered statistically signiﬁcant.
RESULTS: There were no signiﬁcant differences in 
baseline demographics and SF-36v2 scores between the
groups. After 4 weeks of therapy, higher scores in social
functioning (Panax ginseng: 54.9 ± 4.6 vs. placebo: 49.2
± 6.5; p = 0.014), mental health (Panax ginseng: 52.2 ±
7.7 vs. placebo: 47.2 ± 7.3; p = 0.075) and the mental
component summary (Panax ginseng: 51.3 ± 7.4 vs.
placebo: 44.3 ± 8.3; p = 0.019) scales were observed in
patients randomized to Panax ginseng; these differences
did not persist to the 8-week timepoint. No other signif-
icant differences in HRQOL between the groups were
found at the 4- and 8-week timepoints. The incidence of
adverse effects was 33% in the Panax ginseng group 
compared to 17% in the placebo group (p = 0.40). 
Subjects given Panax ginseng (58%) were more likely to
state that they received active therapy than subjects given
placebo (17%; p < 0.05).
CONCLUSIONS: Panax ginseng improves aspects of
mental health and social functioning after a 4 weeks of
therapy although these differences attenuate with 
continued use.
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INFLUENCE OF CAREGIVING ON HEALTH
STATUS OF DEMENTIA CAREGIVERS
Mulchandani D, Nayak RA
St. John’s University, Jamaica, NY, USA
OBJECTIVES: To measure health related quality of life
(HRQOL) of dementia caregivers and to examine 
relationship of caregiving characteristics with caregiver
health status.
METHODS: A convenience sample of 71 caregivers was
selected from local chapters of Alzheimer’s Association in
New York metropolitan area. The caregiver health status
was measured using Short Form 12, Version 2 (SF-12),
general health survey. Hypotheses were formulated and
tested to examine the inﬂuence of caregiving activities on
the self-reported health status of caregivers. Norm-based
physical and mental component summary scores (PCS
and MCS) were computed to investigate associations
between caregiving characteristics and caregiver health
status.
RESULTS: Eighty two percent of the sample were
women. Relatives of the care recipients provided bulk of
caregiving (51%). Professional caregivers who received
ﬁnancial compensation reported higher, statistically sig-
niﬁcant health status scores (PCS = 51.3, p = 0.025; MCS
= 51.2, p = 0.0025) compared to those who did not
receive ﬁnancial compensation (PCS 47.3, p = 0.0165;
MCS = 42.4, p = 0.0005). Higher and signiﬁcant scores
were also reported by caregivers with formal training in
caregiving than those who received no such training (p =
0.009). No signiﬁcant differences were found on HRQOL
scores for caregiving spouses and caregiving children.
There was no association between the health status of
caregivers and the length of time spent in caregiving.
CONCLUSIONS: The type of caregiver relationship to
the care recipient appears to have no bearing on the
HRQOL of caregivers. Financial compensation for care-
giving is associated positively with better health outcomes
for the caregivers. Caregiver health status is not inﬂu-




TREATMENT EFFECTIVENESS OF OLANZAPINE
VERSUS RISPERIDONE IN THE IMPROVEMENT
OF NEGATIVE SYMPTOMS AND QUALITY OF
LIFE IN SCHIZOPHRENIA
Kinon BJ1, Zhao Z2
1Lilly Research Lab, Indianapolis, IN, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: To utilize responder rate to demonstrate
the improvement of negative symptoms and quality of 
life (QoL) associated with olanzapine (OLZ) versus
risperidone (RIS).
METHODS: Data were analyzed post-hoc from a 
large, prospective, randomized, 28-week, double-blind
trial, conducted with 339 patients who met the DSM-IV
criteria for schizophrenia, schizophreniform disorder, or
schizoaffective disorder. Three methods of outcome 
measurement (mean score change, proportion of 
responders and time to response) were used to compare
improvement in the Scale for Assessment of Negative
Symptoms (SANS) and the Quality of Life Scale (QLS)
scores across groups.
RESULTS: At the end of the 28-week treatment, signiﬁ-
cantly more OLZ- than RIS-treated patients reached the
thresholds of 30%, 40% and 50% improvement in SANS
and of 20%, 30% and 40% improvement in QLS. OLZ-
patients also demonstrated a more rapid improvement in
SANS and QLS than RIS-patients.
CONCLUSIONS: The greater effectiveness of OLZ
versus RIS was demonstrated by the greater proportion
of patients who had access to a higher level of clinically
relevant response of negative symptoms and improvement
of QoL. Treatment effectiveness may be a better indica-
tor of the chance of achieving superior functional goals.
